GSK plc Sponsored ADR (GSK)
GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.59 per share a year ago.
GSK delivers solid 2025 results, reaffirms growth outlook for 2026
Specialty Medicines drive strong sales as company maintains guidance and raises dividend GSK PLC (LSE:GSK, NYSE:GSK) reported a 7% rise in sales for 2025 to £32.7 billion, led by strong performance in Specialty Medicines, which grew 17% to £13.5 billion. Sales in HIV, Oncology and Respiratory, Immunology & Inflammation divisions all posted double-digit gains.
GSK's Specialty Medicines Drive Solid Results
The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why GSK (GSK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
GSK snaps up food allergy drug specialist RAPT for $2.2bn
GSK PLC (LSE:GSK, NYSE:GSK) has struck a $2.2 billion deal to buy US biotech firm RAPT Therapeutics, adding a potential new treatment for food allergies to its pipeline. The acquisition gives GSK rights to ozureprubart, a long-acting antibody drug currently in mid-stage trials.
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
